SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $11,712,926,784 |
| Positions | 84 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| MADRIGAL PHARMACEUTICALS INC | MDGL | COM | $1,070,510,235 | 1,993,687 |
| ARGENX SE | ARGX | SPONSORED ADR | $658,202,715 | 709,446 |
| PTC THERAPEUTICS INC | PTCT | COM | $631,875,072 | 7,746,415 |
| PROTAGONIST THERAPEUTICS INC | PTGX | COM | $620,398,832 | 5,061,175 |
| CG ONCOLOGY INC | CGON | COM | $604,961,620 | 8,514,590 |
| INSMED INC | INSM | COM PAR $.01 | $516,347,866 | 4,842,880 |
| TANGO THERAPEUTICS INC | TNGX | COM | $434,533,381 | 13,900,620 |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $377,492,205 | 4,251,996 |
| CELCUITY INC | CELC | COM | $345,758,952 | 3,304,903 |
| ERASCA INC | ERAS | COM | $328,784,533 | 17,946,754 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.